Manuel Hidalgo, MD., PhD
Dr. Hidalgo obtained his MD degree from the University of Navarra and completed training in Medical Oncology at the Hospital ¨12 de Octubre¨ in Madrid. He also obtained a PhD from the Universidad Autónoma of Madrid. From 1997 to 2001, Dr. Hidalgo completed a fellowship in drug development at the University of Texas Health Science Center in San Antonio Institute of Drug Development. During this time Dr. Hidalgo contributed to the development of Erlotinib and Temsirolimus, two of the very first targeted agents to be approved for cancer treatment. In 2001, Dr. Hidalgo moved to Johns Hopkins University to lead the Gastrointestinal Oncology Program. During these years he popularized the use of Avatar mouse models for drug screening, biomarker development and personalized medicine. Dr. Hidalgo joined the Spanish National Cancer Research Center (CNIO) in 2009. His latest research contribution has been the development of Nab-paclitaxel for pancreatic cancer treatment. He is also author of more than 200 original articles, reviews and books chapters in oncology field. Dr. Hidalgo is currently the Director of the Clinical Research Program and the Head of the Gastrointestinal Cancer Tumor Clinical Research Unit at the CNIO and Vice-Director for Translational Research.